We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
7.50 | 0.46% | 1,643.50 | 1,643.00 | 1,644.00 | 1,656.00 | 1,635.00 | 1,642.00 | 2,264,134 | 15:00:06 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.76 | 67.81B |
Date | Subject | Author | Discuss |
---|---|---|---|
31/1/2019 15:40 | Results next week. Sales of Shingrix for 2018 are expected to be about $772 million in 2018 and peak at $4 billion. Another drug that is expected to do well is COPD drug Trelegy Ellipta. Sales are expected to hit about $2.2 billion. | tradermichael | |
31/1/2019 15:29 | Yanks buying. | montyhedge | |
31/1/2019 14:37 | Yanks selling. | montyhedge | |
31/1/2019 14:07 | Thankfully governments are beginning to wake up to the antibiotic resistance crisis, all be it belatedly. Give the pharma companies whatever incentives they need, well with reason, to drive research in this area. | essentialinvestor | |
31/1/2019 13:58 | Dr biotech...don't guess anything. What I dont want is a chief exec who is lauded for being female. I want someone who will increase the share price. Accusations of mysogonism for concerns expressed about Emma's lack of scientific background are a concern. She must be judged on results but is not beyond criticism simply for being female. | zicopele | |
31/1/2019 13:46 | Darwin came from apes? | abdullla | |
31/1/2019 13:42 | Darwin studied medicine, before theology. Zico -Andrew Witty was an economics graduate. I am guessing that you don't like her because she is a woman. I have a PhD in analytical biochemistry, but whilst I understand the basics I would be unable to hold deep conversation about (most) areas of medical research. That would apply to just about anyone - its why you become an expert in your field. What she would need to know is the risk/benefit of any particular project. Unfortunately even having an indepth knowledge about a particular drug doesn't really help in understanding its chances of passing. | dr biotech | |
31/1/2019 13:35 | GSk will return to dividend growth 2020. | montyhedge | |
31/1/2019 13:16 | Zico, I don’t know EM personally, but your argument may not always be true. I am told that Charles Darwin’s degree was in Theology, but many scientists worship him!!( I am a scientist but I don’t).I knew Richard Sykes personally, and Andrew Witty slightly, but not Emma, although I am impressed by some of her decisions and arguments. GSK has not done well in the past few years so change was needed. She is definitely different, so let us give her a chance to perform. | jadeticl3 | |
31/1/2019 13:07 | She has surrounded herself with a team of scientific and business experts. That's the art of higher management. | tradermichael | |
31/1/2019 13:01 | How on earth ca she talk about deep science? No arts graduate is that clever. You need the background or else you lack credibility. | zicopele | |
31/1/2019 13:00 | The Mylan copy was always coming - only surprise is that it took so long. Assuming that GSK cut their price the sales may hang around a bit longer due to the diskus device - some will want to stay with that rather than switching to something else. Ironically is also what Mylan say about the Epipen which they have jacked the price up on multiple times. Must say in the rare cases that I take medication I use generics. Same tablet in a different box in some case. I also tend to look to see where they are made and to see if I trust the lab (if I have been in there). Some are better than others. | dr biotech | |
31/1/2019 12:58 | "She pays close attention to talent development but "can be ruthless with underperformers"." How long before she is ruthless with herself??? | wbecki | |
31/1/2019 12:49 | Emma has removed the old guard and surrounded herself with people who are experts in science. She is an extremely clever person and it has been said that she sets clear objectives and there’s lots of KPIs to measure delivery. She pays close attention to talent development but "can be ruthless with underperformers". | tradermichael | |
31/1/2019 12:36 | @Zico, Nailed it. | wbecki | |
31/1/2019 12:18 | Emma is a poster child for female empowerment. That is all very well but she does not have a background in science. | zicopele | |
31/1/2019 11:38 | Even more pessimistic now. Monty is quoting an article from a young shyster in a smart suit. Please...please do not quote TMF. It is too much to bear. | zicopele | |
31/1/2019 11:31 | Don't worry, Emma will talk about that with the results (next Wednesday). | tradermichael | |
31/1/2019 11:27 | Not what some think, dividend will return to growth.https://www.f | montyhedge | |
31/1/2019 10:57 | I was hoping for another six months to bed downTesaro acquisition and get Shingrix production levels up. Profits will fall this year. Dividend will be cut next year. Shame....should be do good. | zicopele | |
31/1/2019 10:55 | But did you know: Unlike standard paracetamol tablets, GSK's Panadol Advance tablets and Panadol Extra Advance tablets contain Optizorb® Technology which allows the tablets to dissolve rapidly and be absorbed faster than standard paracetamol tablets | tradermichael | |
31/1/2019 10:55 | Most of the large Pharmas distribute generic versions of products that are no longer protected, the major companies have Generic Licenses listed under a subsidiary name. | gbh2 | |
31/1/2019 10:44 | I buy Panadol that are a market leader. Who’s brand is that again. | deanowls | |
31/1/2019 10:40 | btw to say that generic competition will not harm a franchise is nonsense; it will. | alphorn |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions